{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:25:13Z","timestamp":1765758313974},"reference-count":98,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":963,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1111\/ijcp.12100","type":"journal-article","created":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T10:14:04Z","timestamp":1357899244000},"page":"170-180","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications"],"prefix":"10.1155","volume":"67","author":[{"given":"M.","family":"Bennie","sequence":"first","affiliation":[{"name":"Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde; Glasgow UK"},{"name":"Information Services Division; NHS National Services Scotland; Edinburgh UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bishop","sequence":"additional","affiliation":[{"name":"Information Services Division; NHS National Services Scotland; Edinburgh UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Godman","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology; Department of Laboratory Medicine; Karolinska Institutet, Karolinska University Hospital Huddinge; Stockholm Sweden"},{"name":"Institute for Pharmacological Research \u2018Mario Negri\u2019; Milan Italy"},{"name":"Prescribing Research Group; University of Liverpool Management School; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Barbui","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation; Section of Psychiatry; Department of Public Health and Community Medicine; University of Verona; Verona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Raschi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences Pharmacology Unit; Alma Mater Studiorum - University of Bologna; Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Centre for Primary Care: Institute of Population Health; University of Manchester; Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Healthcare Development; Public Healthcare Services Committee Administration, Stockholm County Council; Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. L.","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology; Department of Laboratory Medicine; Karolinska Institutet, Karolinska University Hospital Huddinge; Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2013,1,11]]},"reference":[{"key":"10.1111\/ijcp.12100-BIB0001|ijcp12100-cit-0001","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1586\/14737167.8.4.357","article-title":"Insight into recent reforms and initiatives in Austria; implications for key stakeholders","volume":"8","author":"Godman","year":"2008","journal-title":"Expert Rev Pharmacoeconomcis Outcomes Res"},{"key":"10.1111\/ijcp.12100-BIB0002|ijcp12100-cit-0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF03256162","article-title":"Ongoing pharmaceutical reforms in France; implications for key stakeholder groups","volume":"8","author":"Sermet","year":"2010","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1111\/ijcp.12100-BIB0003|ijcp12100-cit-0003","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/erp.09.58","article-title":"Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction","volume":"9","author":"Coma","year":"2009","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1111\/ijcp.12100-BIB0004|ijcp12100-cit-0004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2165\/00019053-200826070-00001","article-title":"Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe","volume":"26","author":"Wettermark","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/ijcp.12100-BIB0005|ijcp12100-cit-0005","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/ph3082470","article-title":"Use of generics - a critical cost containment measure for all healthcare professionals in Europe?","volume":"3","author":"Godman","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1111\/ijcp.12100-BIB0006|ijcp12100-cit-0006","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/erp.11.42","article-title":"Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe; implications for the future","volume":"11","author":"Von\u010dina","year":"2011","journal-title":"Expert Rev Pharmacoeconomics and Outcomes Res"},{"key":"10.1111\/ijcp.12100-BIB0007|ijcp12100-cit-0007","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/erp.10.72","article-title":"Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications","volume":"10","author":"Godman","year":"2010","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.1111\/ijcp.12100-BIB0008|ijcp12100-cit-0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2010.00141","article-title":"Policies to enhance prescribing efficiency in Europe: findings and future implications","volume":"1","author":"Godman","year":"2011","journal-title":"Frontiers Pharmacol"},{"key":"10.1111\/ijcp.12100-BIB0009|ijcp12100-cit-0009","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00228-008-0537-z","article-title":"Enhancing the rational use of new medicines across European healthcare systems - a position paper","volume":"64","author":"Garattini","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/ijcp.12100-BIB0010|ijcp12100-cit-0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00019053-200826020-00001","article-title":"Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies","volume":"26","author":"Godman","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/ijcp.12100-BIB0011|ijcp12100-cit-0011","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1742-1241.2009.02129.x","article-title":"Potential savings without compromising the quality of care","volume":"63","author":"Norman","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12100-BIB0012|ijcp12100-cit-0012","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1586\/erp.10.87","article-title":"Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs","volume":"11","author":"Godman","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1111\/ijcp.12100-BIB0013|ijcp12100-cit-0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.7175\/rhc.v3i1.55","article-title":"Prescribing restrictions - a necessary strategy among some European countries to enhance future prescribing efficiency?","volume":"3","author":"Godman","year":"2012","journal-title":"Rev Health Care"},{"key":"10.1111\/ijcp.12100-BIB0014|ijcp12100-cit-0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/erp.09.73","article-title":"Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK; impact and implications","volume":"10","author":"McGinn","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1111\/ijcp.12100-BIB0015|ijcp12100-cit-0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1742-7843.2011.00682.x","article-title":"The \u201cWise List\u201d - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm","volume":"108","author":"Gustafsson","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/ijcp.12100-BIB0016|ijcp12100-cit-0016","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/erp.11.98","article-title":"Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland","volume":"12","author":"Bennie","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1111\/ijcp.12100-BIB0017|ijcp12100-cit-0017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/erp.11.24","article-title":"European countries with small populations can obtain low prices for drugs: Lithuania as a case history","volume":"11","author":"Garuoliene","year":"2011","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.1111\/ijcp.12100-BIB0018|ijcp12100-cit-0018","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/14737167.8.6.549","article-title":"Generic olanzapine: health authority opportunity or nightmare?","volume":"8","author":"Araszkiewicz","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1111\/ijcp.12100-BIB0019|ijcp12100-cit-0019","unstructured":"SIGN Dyspepsia - a national clinical guideline http:\/\/www.sign.ac.uk\/pdf\/sign68.pdf"},{"key":"10.1111\/ijcp.12100-BIB0020|ijcp12100-cit-0020","unstructured":"SIGN Secondary prevention of CHD following Myocardial Infarction 2000 http:\/\/www.nhsggc.org.uk\/content\/mediaassets\/pdf\/HSD\/sign41.pdf"},{"key":"10.1111\/ijcp.12100-BIB0021|ijcp12100-cit-0021","unstructured":"SIGN Management of Diabetes 2010 http:\/\/www.sign.ac.uk\/sign116.pdf"},{"key":"10.1111\/ijcp.12100-BIB0022|ijcp12100-cit-0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11318840-000000000-00000","article-title":"Patient co-payments do influence atypical antipsychotic choice in Poland; implications once generic atypcials are available","volume":"9","author":"Wladysiuk","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1111\/ijcp.12100-BIB0023|ijcp12100-cit-0023","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijlp.2005.08.007","article-title":"Economic issues in access to medications: schizophrenia treatment in England","volume":"28","author":"Knapp","year":"2005","journal-title":"Int J Law Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0024|ijcp12100-cit-0024","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/pds.1162","article-title":"Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002","volume":"15","author":"Mirandola","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/ijcp.12100-BIB0025|ijcp12100-cit-0025","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1377\/hlthaff.28.5.w770","article-title":"Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges","volume":"28","author":"Crystal","year":"2009","journal-title":"Health Aff"},{"key":"10.1111\/ijcp.12100-BIB0026|ijcp12100-cit-0026","unstructured":"NICE implementation uptake report: atypical antipsychotic drugs for the treatment of schizophrenia NICE Technology appraisals http:\/\/www.nice.org.uk\/media\/410\/E9\/ImplUptakeReportAtypicalAntipsychotics.pdf"},{"key":"10.1111\/ijcp.12100-BIB0027|ijcp12100-cit-0027","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1440-1614.2003.01110.x","article-title":"Use of antipsychotic medications in Australia between July 1995 and December 2001","volume":"37","author":"Mond","year":"2003","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0028|ijcp12100-cit-0028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12100-BIB0029|ijcp12100-cit-0029","article-title":"Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics","author":"Kishimoto","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0030|ijcp12100-cit-0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995-2008","volume":"20","author":"Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/ijcp.12100-BIB0031|ijcp12100-cit-0031","first-page":"e109","article-title":"Off-label use of antipsychotic medications in medicaid","volume":"18","author":"Leslie","year":"2012","journal-title":"Am J Manag Care"},{"key":"10.1111\/ijcp.12100-BIB0032|ijcp12100-cit-0032","unstructured":"Fisk M Feeley J Voreacos D. J&J Said to Agree to $2.2 Billion Drug Marketing Accord http:\/\/www.bloomberg.com\/news\/2012-06-11\/j-j-said-to-pay-2-2-billion-to-end-risperdal-sales-probe.html"},{"key":"10.1111\/ijcp.12100-BIB0033|ijcp12100-cit-0033","unstructured":"Department of Justice settlement agreement http:\/\/www.justice.gov\/usao\/pae\/Pharma-Device\/astrazeneca_settlementagreement.pdf"},{"key":"10.1111\/ijcp.12100-BIB0034|ijcp12100-cit-0034","unstructured":"Jack A AstraZeneca faces $520\u00a0m Seroquel fine http:\/\/www.ft.com\/cms\/s\/0\/319e31d4-5251-11df-8b09-00144feab49a.html#axzz26q1gMSgc"},{"key":"10.1111\/ijcp.12100-BIB0035|ijcp12100-cit-0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2710.2006.00711.x","article-title":"Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents","volume":"31","author":"Ren","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/ijcp.12100-BIB0036|ijcp12100-cit-0036","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4088\/JCP.v64n0515","article-title":"Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis","volume":"64","author":"Taylor","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0037|ijcp12100-cit-0037","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","article-title":"Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors","volume":"30","author":"Valenstein","year":"2004","journal-title":"Schizophr Bull"},{"key":"10.1111\/ijcp.12100-BIB0038|ijcp12100-cit-0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200418010-00001","article-title":"Neuropsychotherapeutics in the UK. What has been the impact of NICE on prescribing?","volume":"18","author":"Walley","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1111\/ijcp.12100-BIB0039|ijcp12100-cit-0039","unstructured":"NICE Schizophrenia - Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care http:\/\/www.nice.org.uk\/nicemedia\/live\/11786\/43610\/43610.pdf"},{"key":"10.1111\/ijcp.12100-BIB0040|ijcp12100-cit-0040","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12100-BIB0041|ijcp12100-cit-0041","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(08)61765-1","article-title":"The spurious advance of antipsychotic drug therapy","volume":"373","author":"Tyrer","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12100-BIB0042|ijcp12100-cit-0042","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"Modern antipsychotic drugs: a critical overview","volume":"172","author":"Gardner","year":"2005","journal-title":"CMAJ"},{"key":"10.1111\/ijcp.12100-BIB0043|ijcp12100-cit-0043","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00127-005-0852-y","article-title":"Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy","volume":"40","author":"Andretta","year":"2005","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"10.1111\/ijcp.12100-BIB0044|ijcp12100-cit-0044","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00002018-200528010-00003","article-title":"Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death","volume":"28","author":"Titier","year":"2005","journal-title":"Drug Saf"},{"key":"10.1111\/ijcp.12100-BIB0045|ijcp12100-cit-0045","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1111\/ijcp.12100-BIB0046|ijcp12100-cit-0046","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"NEJM"},{"key":"10.1111\/ijcp.12100-BIB0047|ijcp12100-cit-0047","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/11318880-000000000-00000","article-title":"Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly","volume":"26","author":"Vieweg","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1111\/ijcp.12100-BIB0048|ijcp12100-cit-0048","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pds.1746","article-title":"Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)","volume":"18","author":"Poluzzi","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/ijcp.12100-BIB0049|ijcp12100-cit-0049","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11096-011-9541-y","article-title":"Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case","volume":"33","author":"Meyer-Massetti","year":"2011","journal-title":"Int J Clin Pharm"},{"key":"10.1111\/ijcp.12100-BIB0050|ijcp12100-cit-0050","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12100-BIB0051|ijcp12100-cit-0051","unstructured":"US FDA Information for Healthcare Professionals: Conventional Antipsychotics http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm124830.htm"},{"key":"10.1111\/ijcp.12100-BIB0052|ijcp12100-cit-0052","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12100-BIB0053|ijcp12100-cit-0053","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1176\/appi.ajp.2011.11010039","article-title":"Commentary - the NIM H-CAT ie schizophrenia study: what did we learn?","volume":"168","author":"Lieberman","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0054|ijcp12100-cit-0054","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4088\/JCP.10m06497","article-title":"The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state","volume":"73","author":"Berkowitz","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0055|ijcp12100-cit-0055","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ijcp.12100-BIB0056|ijcp12100-cit-0056","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006626.pub2","article-title":"Risperidone versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ijcp.12100-BIB0057|ijcp12100-cit-0057","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00023210-200519050-00003","article-title":"Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review","volume":"19","author":"Hargreaves","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1111\/ijcp.12100-BIB0058|ijcp12100-cit-0058","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics","volume":"163","author":"Heres","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0059|ijcp12100-cit-0059","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/appi.ajp.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0060|ijcp12100-cit-0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2008.09.031","article-title":"Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial","volume":"107","author":"Rosenheck","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1111\/ijcp.12100-BIB0061|ijcp12100-cit-0061","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/j.1440-1614.2005.01509.x","article-title":"Assessing cost-effectiveness of drug interventions for schizophrenia","volume":"39","author":"Magnus","year":"2005","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0062|ijcp12100-cit-0062","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/JCP.0b013e31820597fa","article-title":"The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia","volume":"31","author":"Glick","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/ijcp.12100-BIB0063|ijcp12100-cit-0063","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10597-005-5981-y","article-title":"Clinical equivalence of generic clozapine","volume":"41","author":"Healy","year":"2005","journal-title":"Community Ment Health J"},{"key":"10.1111\/ijcp.12100-BIB0064|ijcp12100-cit-0064","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4088\/JCP.v67n0706","article-title":"Evaluation of an interchangeability switch in patients treated with clozapine: a retrospective review","volume":"67","author":"Alessi-Severini","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0065|ijcp12100-cit-0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1192\/bjp.bp.105.017079","article-title":"Generic clozapine: outcomes after switching","volume":"89","author":"Paton","year":"2006","journal-title":"Br J Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0066|ijcp12100-cit-0066","first-page":"720","article-title":"Generic clozapine in schizophrenia: what is all the fuss about?","volume":"173","author":"Bazire","year":"2004","journal-title":"Pharmaceutical J"},{"key":"10.1111\/ijcp.12100-BIB0067|ijcp12100-cit-0067","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5414\/CP201509","article-title":"Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2\u00a0mg risperidone in healthy Thai male volunteers","volume":"49","author":"Khorana","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1111\/ijcp.12100-BIB0068|ijcp12100-cit-0068","unstructured":"Correl C Carbon M Brand vs. generic psychotropic medication. Is one better than the other? https:\/\/www.nwpmd.com\/LinkClick.aspx?fileticket=vr6K7kfBUfc%3D&tabid=342"},{"key":"10.1111\/ijcp.12100-BIB0069|ijcp12100-cit-0069","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1755-5949.2010.00210.x","article-title":"Switching from brand-name to generic psychotropic medications: a literature review","volume":"17","author":"Desmarais","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1111\/ijcp.12100-BIB0070|ijcp12100-cit-0070","first-page":"30","article-title":"Getting better value from the NHS drug budget","volume":"342","author":"Moon","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/ijcp.12100-BIB0071|ijcp12100-cit-0071","first-page":"73","article-title":"WHO model list of essential medicines and developed countries: a comparison with the Lothian joint formulary","volume":"20","author":"Hems","year":"2006","journal-title":"WHO Drug Information"},{"key":"10.1111\/ijcp.12100-BIB0072|ijcp12100-cit-0072","unstructured":"Lothian Formulary http:\/\/www.ljf.scot.nhs.uk\/LothianJointFormularies\/Adult\/4.0\/4.2\/4.2.1\/(a)\/Pages\/default.aspx"},{"key":"10.1111\/ijcp.12100-BIB0073|ijcp12100-cit-0073","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1365-2753.2001.00280.x","article-title":"Hawthorne effects and research into clinical practice","volume":"7","author":"Holden","year":"2001","journal-title":"J Eval Clin Practice"},{"key":"10.1111\/ijcp.12100-BIB0074|ijcp12100-cit-0074","first-page":"1","article-title":"Pragmatic trials: how to adjust for the \u2018Hawthorne effect\u2019?","volume":"-","author":"Konstantinou","year":"2011","journal-title":"Thorax"},{"key":"10.1111\/ijcp.12100-BIB0075|ijcp12100-cit-0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1748-5908-4-6","article-title":"A cluster randomized controlled trial aimed at implementation of local quality improvement collaboratives to improve prescribing and test ordering performance of general practitioners: Study Protocol","volume":"4","author":"Trietsch","year":"2009","journal-title":"Implement Sci"},{"key":"10.1111\/ijcp.12100-BIB0076|ijcp12100-cit-0076","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jclinepi.2004.03.009","article-title":"Block design allowed for control of the Hawthorne effect in a randomized controlled trial of test ordering","volume":"57","author":"Verstappen","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/ijcp.12100-BIB0077|ijcp12100-cit-0077","unstructured":"Godman B Actions to improve the efficient and safe use of drugs: what can we learn from international experiences? http:\/\/www10.gencat.cat\/catsalut\/archivos\/jornades\/farmacia\/8a\/Conferencia_inaugural_Godman.pdf"},{"key":"10.1111\/ijcp.12100-BIB0078|ijcp12100-cit-0078","unstructured":"World Health Organisation (WHO) Guidelines for ATC Classification and DDD Assignment 2009 Oslo WHO Collaborating Centre for Drug Statistics Methodology www.whocc.no"},{"key":"10.1111\/ijcp.12100-BIB0079|ijcp12100-cit-0079","unstructured":"World Health Organization (WHO) Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/Drug%20utilization%20research.pdf"},{"key":"10.1111\/ijcp.12100-BIB0080|ijcp12100-cit-0080","first-page":"CD006633","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","volume":"Nov 10; (11)","author":"Asenjo Lobos","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ijcp.12100-BIB0081|ijcp12100-cit-0081","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1017\/S1461145710001380","article-title":"Evidence-based pharmacotherapy of schizophrenia","volume":"14","author":"Leucht","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12100-BIB0082|ijcp12100-cit-0082","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/157488611797579230","article-title":"Clozapine safety, 35\u00a0years later","volume":"6","author":"Raja","year":"2011","journal-title":"Curr Drug Saf"},{"key":"10.1111\/ijcp.12100-BIB0083|ijcp12100-cit-0083","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11096-010-9366-0","article-title":"Coping with changes in defined daily dose in longitudinal drug consumption databases","volume":"32","author":"Vlahovic-Palcevski","year":"2010","journal-title":"Pharm World Sci"},{"key":"10.1111\/ijcp.12100-BIB0084|ijcp12100-cit-0084","first-page":"07","volume-title":"Sage University Papers Series on Quantitative Applications in the Social Sciences","author":"McDowall","year":"1980"},{"key":"10.1111\/ijcp.12100-BIB0085|ijcp12100-cit-0085","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/jama.1993.03510160055029","article-title":"Examining product risk in context. Market withdrawal of zomepirac as a case study","volume":"270","author":"Ross-Degnan","year":"1993","journal-title":"J Am Med Assoc"},{"key":"10.1111\/ijcp.12100-BIB0086|ijcp12100-cit-0086","first-page":"409","article-title":"Testing for serial correlation in least square regression","volume":"37","author":"Durbin","year":"1951","journal-title":"Biometrika"},{"key":"10.1111\/ijcp.12100-BIB0087|ijcp12100-cit-0087","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/bmj.309.6956.727","article-title":"Interpreting the results of observational research: chance is not such a fine thing","volume":"309","author":"Brennan","year":"1994","journal-title":"BMJ"},{"key":"10.1111\/ijcp.12100-BIB0088|ijcp12100-cit-0088","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5655\/smr.v4i2.1004","article-title":"Pharmaceutical policies in European countries in response to the global financial crisis","volume":"4","author":"Vogler","year":"2011","journal-title":"South Med Rev"},{"key":"10.1111\/ijcp.12100-BIB0089|ijcp12100-cit-0089","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.1111\/ijcp.12100-BIB0090|ijcp12100-cit-0090","unstructured":"Scottish Quality Prescribing Initiative 2012 www.sehd.scot.nhs.uk\/pca\/PCA2012(M)08.pdf"},{"key":"10.1111\/ijcp.12100-BIB0091|ijcp12100-cit-0091","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/erp.12.23","article-title":"The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia","volume":"12","author":"Chue","year":"2012","journal-title":"Exp Rev Pharmacoecon Outcome Res"},{"key":"10.1111\/ijcp.12100-BIB0092|ijcp12100-cit-0092","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-244X-12-25","article-title":"Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database","volume":"12","author":"Lambert","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0093|ijcp12100-cit-0093","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10198-009-0215-9","article-title":"The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden","volume":"11","author":"Willis","year":"2010","journal-title":"Eur J Health Econ"},{"key":"10.1111\/ijcp.12100-BIB0094|ijcp12100-cit-0094","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.11m07070","article-title":"Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia","volume":"73","author":"Rosenheck","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0095|ijcp12100-cit-0095","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4088\/JCP.11m07074","article-title":"Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial","volume":"73","author":"Covell","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12100-BIB0096|ijcp12100-cit-0096","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0447.2009.01352.x","article-title":"Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use","volume":"120","author":"Taylor","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/ijcp.12100-BIB0097|ijcp12100-cit-0097","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clinthera.2010.01.008","article-title":"Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands","volume":"32","author":"Pechlivanoglou","year":"2010","journal-title":"Clin Ther"},{"key":"10.1111\/ijcp.12100-BIB0098|ijcp12100-cit-0098","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/npp.2010.111","article-title":"Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial","volume":"35","author":"Gaebel","year":"2010","journal-title":"Neuropsychopharmacology"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12100","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:03:48Z","timestamp":1643349828000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,11]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12100","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1,11]]},"assertion":[{"value":"2013-01-11","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}